Literature DB >> 12801118

Extemporaneous (magistral) preparation of oral medicines for children in European hospitals.

F Brion1, A J Nunn, A Rieutord.   

Abstract

AIM: To evaluate methods of preparation of oral medicines in European children's hospitals when drugs prescribed are unlicensed or off-label, and to determine whether such extemporaneously prepared medicines are available as suitable, authorized products in other countries.
METHODS: A questionnaire was distributed to 41 hospital pharmacists in 18 European countries, requesting information on the most frequent extemporaneously prepared oral liquid, powder and capsule medicines, and on their formulation and stability. Information was gathered on the availability of suitable authorized forms of these medicines in other European countries, the USA and Australia.
RESULTS: 21 questionnaires from 16 countries returned showed that the methods of extemporaneous preparation vary in different European countries with, for example, liquid preparations predominating in England and Sweden, capsules in France and Spain, and powders in Finland and Italy. The top 20 preparations are made in many different strengths and formulations. The same drug may be prepared in liquid, capsule or powder form, depending on the country. Many of the extemporaneous preparations were available as suitable authorized paediatric medicines in other countries. The quality of information available on formulation and stability was limited, and there was concern about the availability and quality of chemical ingredients.
CONCLUSION: Preparation of children's oral medicines is subject to much variation in hospitals throughout Europe and there is little harmonization of formulations or information on stability of products. The European Union could be the focus for improving the availability of appropriate authorized medicines for children and ensuring that when extemporaneous preparation is necessary it is of a common high standard.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12801118     DOI: 10.1111/j.1651-2227.2003.tb00583.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  16 in total

1.  Establishing a baseline for the monitoring of medicines availability for children in the UK: 1998-2002.

Authors:  Komathi Balakrishnan; June Tordoff; Pauline Norris; David Reith
Journal:  Br J Clin Pharmacol       Date:  2006-07-26       Impact factor: 4.335

2.  Effectiveness of Antimicrobial Preservation of Extemporaneous Diluted Simple Syrup Vehicles for Pediatrics.

Authors:  Ana Santoveña-Estévez; Javier Suárez-González; Martín Vera; Cristina González-Martín; Mabel Soriano; José B Fariña
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Sep-Oct

3.  Licensing and labelling of drugs in a paediatric oncology ward.

Authors:  Henk van den Berg; Nanda Tak
Journal:  Br J Clin Pharmacol       Date:  2011-09       Impact factor: 4.335

4.  Off-label and unlicensed drug use in neonatal intensive care units in Turkey: the old-inn study.

Authors:  S Suna Oguz; H Gozde Kanmaz; Ugur Dilmen
Journal:  Int J Clin Pharm       Date:  2012-01-11

Review 5.  A literature review on off-label drug use in children.

Authors:  Chiara Pandolfini; Maurizio Bonati
Journal:  Eur J Pediatr       Date:  2005-05-24       Impact factor: 3.183

6.  Prescribing Pattern of Dermatological Compounding in Ethiopia: The Case of ALERT Hospital.

Authors:  Muluken Nigatu Selam; Andualem Ababu; Regasa Bayisa; Mahdi Abdella; Edessa Diriba; Minychel Wale; Tadesse Alemu; Tesfa Marew; Assefa Mulu Baye
Journal:  Integr Pharm Res Pract       Date:  2022-01-06

7.  [Pharmacodynamic and pharmacokinetic characteristics of pain therapy in neonates: Austrian interdisciplinary recommendations on pediatric perioperative pain management].

Authors:  W Jaksch; B Messerer; B Keck; A Lischka; B Urlesberger
Journal:  Schmerz       Date:  2014-02       Impact factor: 1.107

8.  Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions.

Authors:  Hudson C Polonini; Sharlene L Silva; Thalyta R de Almeida; Marcos Antônio F Brandão; Anderson O Ferreira
Journal:  Eur J Hosp Pharm       Date:  2016-03-24

Review 9.  Dosage and formulation issues: oral vitamin E therapy in children.

Authors:  Tone Westergren; Betty Kalikstad
Journal:  Eur J Clin Pharmacol       Date:  2009-10-13       Impact factor: 2.953

10.  How to improve the implementation of academic clinical pediatric trials involving drug therapy? A qualitative study of multiple stakeholders.

Authors:  Delphine Girard; Olivier Bourdon; Hendy Abdoul; Sonia Prot-Labarthe; Françoise Brion; Annick Tibi; Corinne Alberti
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.